Greenwich LifeSciences $12.5M Cash Position and FLAMINGO-01 Trial Analysis

Based on my comprehensive research, I can now provide you with a detailed analysis of Greenwich LifeSciences’ $12.5 million cash balance and its implications for clinical trials and operational runway.

---

Greenwich LifeSciences, Inc. (NASDAQ: GLSI) reported a cash balance of approximately

as of January 23, 2026, following capital raised through its At-The-Market (ATM) financing program [1][2]. This represents a significant improvement from the approximately $6 million cash position carried into the year, successfully lifting the company’s liquidity to support its ongoing Phase 3 FLAMINGO-01 clinical trial.

---

The company’s financial strategy has been characterized by disciplined cost management, with a

, and a full-year 2025 burn of $9.5 million [3][4]. This burn rate encompasses:

• Clinical trial operations
  for the FLAMINGO-01 Phase 3 study
• Manufacturing costs
  for GP2 immunotherapy product
• Research and development activities
• General administrative expenses

The company has implemented several cost-reduction initiatives, including transitioning U.S. trial operations in-house, which has contributed to maintaining a lean operational structure [5].

---

Based on the current $12.5 million cash balance and the 2025 annual burn rate of $9.5 million, the company’s cash position

[3]. This provides a runway of approximately depending on actual cash consumption, which represents a comfortable position for a clinical-stage biotechnology company.

The ATM financing strategy has proven effective in managing the company’s capital requirements without resorting to larger, more dilutive financing rounds. The company has been described as using this facility “judiciously and efficiently” to maintain adequate cash reserves while limiting near-term dilution [4].

Several factors support the company’s relatively efficient capital utilization:

Factor	Impact
ATM Financing	Allows flexible, market-tuned capital raising
In-house trial operations	Reduces outsourcing costs
Cost-reduction measures	Lowers overall operational expenses
FDA-approved manufacturing	Ensures uninterrupted trial supply

---

The $12.5 million cash position directly supports the continuation of the

, which is evaluating GLSI-100 (GP2 immunotherapy) for the prevention of breast cancer recurrence in high-risk patients [6][7]. Key trial characteristics include:

• Enrollment target:
  Up to 750 patients
• Geographic scope:
  Approximately 140 sites across the United States, Europe, Canada, and the United Kingdom
• Trial design:
  Double-blinded, placebo-controlled study
• Patient population:
  High-risk patients with residual disease or at high risk of recurrence

A significant recent development was the

for use in the FLAMINGO-01 trial on January 22, 2026 [8][9]. This milestone ensures:

• Uninterrupted supply of clinical trial materials
• Validation of commercial-scale manufacturing capabilities
• Reduced manufacturing-related risks for the trial

---

1. Adequate near-term funding:
   The current cash position provides sufficient runway through 2026, reducing immediate financing pressure
2. Managing dilution:
   ATM financing is being used strategically to limit near-term dilutive financings and preserve partnership value
3. Operational efficiency:
   Cost-reduction measures and in-house operations demonstrate fiscal discipline
4. Trial momentum:
   Active enrollment across ~140 sites indicates operational execution capability

1. Longer-term funding needs:
   Beyond 2026, additional financing will likely be required depending on trial progression
2. Clinical trial outcomes:
   The ultimate value of the cash position depends on successful trial execution and results
3. Market conditions:
   Future financing costs will depend on market conditions and company progress
4. Partnership strategy:
   The company has indicated partnering plans, which may affect future capital requirements [5]

---

Greenwich LifeSciences’ $12.5 million cash balance represents a

financial position for a clinical-stage biotechnology company. The current capital provides sufficient runway to complete all of 2026 operations, including the critical FLAMINGO-01 Phase 3 trial, without immediate financing concerns.

The company’s use of ATM financing, combined with operational cost reductions, demonstrates a prudent approach to capital management. However, investors should note that the ultimate value of this cash position will be determined by clinical trial outcomes, with additional financing likely needed depending on trial timelines and results.

The recent FDA approval of commercial GP2 manufacturing for the trial represents a significant de-risking milestone that supports uninterrupted trial operations through 2026 and beyond.

---

[1] Street Insider - “Greenwich LifeSciences raises cash balance to $12.5 million through ATM” (https://www.streetinsider.com/Corporate+News/Greenwich+LifeSciences+raises+cash+balance+to+%2412.5+million+through+ATM/25895280.html)

[2] GlobeNewswire - “Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01” (https://www.globenewswire.com/en/news-release/2026/01/22/3223531/0/en/Greenwich-LifeSciences-Announces-FDA-Approves-Use-of-Commercially-Manufactured-GP2-in-FLAMINGO-01.html)

[3] Barchart - “Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy” (https://www.barchart.com/story/news/37243966/greenwich-lifesciences-provides-update-on-flamingo-01-cash-burn-rate-and-financing-strategy)

[4] MarketBeat - “Greenwich LifeSciences (GLSI) FDA Approvals” (https://www.marketbeat.com/stocks/NASDAQ/GLSI/fda-events/)

[5] Nasdaq - “Greenwich Life Sciences Provides Updates On Breast Cancer Study; Outlines Corporate Strategy” (https://www.nasdaq.com/articles/greenwich-life-sciences-provides-updates-breast-cancer-study-outlines-corporate-strategy)

[6] Greenwich LifeSciences Official Website (https://greenwichlifesciences.com/)

[7] Greenwich LifeSciences PDF - GLSI-100 Clinical Trial Information (https://greenwichlifesciences.com/wp-content/uploads/2025/08/GLSI_20250820_27715.pdf)

[8] Benzinga - “Greenwich LifeSciences Stock Jumps After FDA Update” (https://www.benzinga.com/trading-ideas/movers/26/01/50072749/greenwich-lifesciences-stock-jumps-after-fda-update)

[9] GuruFocus - “Greenwich LifeSciences (GLSI) Surges 33% on FDA Approval for GP2 Lot” (https://www.gurufocus.com/news/8542547/greenwich-lifesciences-glsi-surges-33-on-fda-approval-for-gp2-lot)